Can we test for hereditary cancer at 18 years when we start surveillance at 25? Patient reported outcomes

Author： Sie Aisha   Prins Judith   Spruijt Liesbeth   Kets C.   Hoogerbrugge Nicoline  

Publisher： Springer Publishing Company

ISSN： 1389-9600

Source： Familial Cancer, Vol.12, Iss.4, 2013-12, pp. : 675-682

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Development of targeted therapies for triple-negative breast cancer: can we harness tumor heterogeneity to improve patient outcomes?

By Diamond Jennifer R   Elias Anthony D  

Breast Cancer Management, Vol. 2, Iss. 3, 2013-05 ,pp. : 175-178

Future Medicine

Access to resources Recommend Favorite

Familial breast cancer in southern Finland - how prevalent are breast cancer families and can we trust the family history reported by patients?

By Eerola H.   Blomqvist C.   Pukkala E.   Pyrhonen S.   Nevanlinna H.  

European Journal of Cancer, Vol. 36, Iss. 9, 2000-06 ,pp. : 1143-1148

Elsevier

Access to resources Recommend Favorite

New Treatments for Bladder Cancer: When Will We Make Progress?

By Nadal Rosa   Bellmunt Joaquim  

Current Treatment Options in Oncology, Vol. 15, Iss. 1, 2014-03 ,pp. : 99-114

Springer Publishing Company

Access to resources Recommend Favorite

Editorial: Tailoring treatment to patients with early breast cancer - can we deliver?

By Gui Gerald  

The Women's Oncology Review, Vol. 4, Iss. 2, 2004-06 ,pp. : 69-71

Informa Healthcare

Access to resources Recommend Favorite

How can we improve survival from breast cancer in developing countries?

By Sankaranarayanan Rengaswamy   Alwan Nada   Denny Lynette  

Breast Cancer Management, Vol. 2, Iss. 3, 2013-05 ,pp. : 179-183

Future Medicine

Access to resources Recommend Favorite